ASTRAZENECA, the pha­r­maceutical giant which virtually became a household name during the Covid-19 pandemic, has admitted that its Covishield vaccine could cause rare side effects, including blood clots and low platelet count.

The pharma giant is being sued in a class action over claims that its vaccine, developed with the University of Oxford, caused death and serious injury in dozens of cases.

“It is admitted that the AZ vaccine can, in very rare cases, cause TTS (Thrombosis with Thrombocytopenia Syndrome). The causal mechanism is not known,” the company said in court documents, The Telegraph reported.

Covishield was developed by the British-Swedish company in collaboration with Oxford University, and produced by the Serum Institute of India. It was widely administered in over 150 countries.

Some studies conducted during the pandemic found the vaccine was 60 to 80 per cent effective in protecting against the novel coronavirus, according to The Independent.

But one of the complainants alleged that the vaccine caused him a permanent brain injury after he developed a blood clot, preventing him from working.

While the company has contested these claims, the court submission marks the first time it has admitted that the vaccine can cause side-effects that are characterised by blood clots and a low blood platelet count in humans.

“Further, TTS can also occur in the absence of the AZ vaccine (or any vaccine). Causation in any individual case will be a matter for expert evidence,” it added.

The admission by AstraZeneca runs counter to the company’s insistence in 2023 that it would “not accept that TTS is caused by the vaccine at a generic level”, according to The Independent.

Scientists first identified a link between the vaccine and a new illness called vaccine-induced immune thrombocytopenia and thrombosis (VITT) in March 2021.

The UK government has indemnified Astra­Zeneca against any legal action but has so far refused to intervene, according to The Telegraph.

According to the Council for International Organisat­ions of Medical Sciences, “very rare” side effects are those reported in less than 1 in 10,000 cases.

Published in Dawn, May 1st, 2024

Opinion

Editorial

Regional climbdown
04 Mar, 2026

Regional climbdown

WITH the region in flames, Pakistan must calibrate its foreign policy accordingly; it has to deal with some ...
Burning questions
Updated 04 Mar, 2026

Burning questions

BY most accounts, the protest was not massive. Nor was it unexpected. And yet, it ended in gruesome bloodshed. The...
Governance failure
04 Mar, 2026

Governance failure

BENEATH Lahore’s signal-free corridors and road infrastructure lies a darker truth: crumbling sewerage lines,...
Iran endgame
Updated 03 Mar, 2026

Iran endgame

AS hostilities continue following the Israeli-American joint aggression against Iran, there seems to be no visible...
Water concerns
03 Mar, 2026

Water concerns

RECENT reports that India plans to invest $60bn in increasing its water storage capacity on the Jhelum and Chenab...
Down and out
03 Mar, 2026

Down and out

ANOTHER Twenty20 World Cup, another ignominious exit — although this time Pakistan did advance past the first...